Citations

Showing 10 of 108081 citations.

Secretory diarrhea and hypokalemia associated with colonic pseudo‐obstruction: A case study and systematic analysis of the literature
Haffar, Samir , Szarka, Lawrence A., Murad, M. Hassan , Camilleri, Michael , Camilleri, M , Bazerbachi, Fateh , Wang, Zhen , Prokop, Larry J. , Murad, M Hassan

Mayo Clinic

Neurogastroenterology & Motility | June 5, 2017 | Volume: 29 | Issue: 11 | Pages: No page available

10.1111/nmo.13120 | PMID 28580600 Get It

AbstractBackgroundColonic pseudo‐obstruction (CPO) is characterized by colonic distention in the absence of mechanical obstruction or toxic megacolon. Concomitant secretory diarrhea (SD) with hypokalemia (SD‐CPO) due to gastrointestinal (GI) loss requires further characterization.AimTo perform a systematic review of SD‐CPO, report a case study, and compare SD‐CPO with classical CPO (C‐CPO).MethodsWe performed a search of MEDLINE, EMBASE, Cochrane, and Scopus for reports based on a priori criteria for CPO, SD and GI loss of potassium. An additional case at Mayo Clinic was included.ResultsNine publications met inclusion criteria, with a total of 14 cases. Six studies had high, three moderate, and our case high methodological quality. Median age was 74 years (66‐97), with 2:1 male/female ratio. Kidney disease was present in 6/14 patients. Diarrhea was described as profuse, watery, or viscous in 10 patients. Median serum, stool, and urine potassium concentrations (mmol/L) were 2.4 (range: 1.9‐3.1), 137 (100‐180), and 17 (8‐40), respectively. Maximal diameter of colon and cecum (median) were 10.2 cm and 10.5 cm, respectively. Conservative therapy alone was effective in five out of 14 patients. Median potassium supplementation was 124 mEq/d (40‐300). Colonic decompression was effective in three out of six patients; one had a total colectomy; three out of 14 had died. The main differences between SD‐CPO and C‐CPO were lower responses to treatments: conservative measures (35.7% vs 73.6%, P=.01), neostigmine (17% vs 89.2%, P<.001), and colonic decompression (50% vs 82.4%, P=.02).ConclusionSD‐CPO is a rare phenotype associated with increased fecal potassium and is more difficult to treat than C‐CPO.
Underreported use of palliative care and patient-reported outcome measures to address reduced quality of life in patients with calciphylaxis: a systematic review
Riemer, Christie , Wu, Kelly L. , Strand, Jacob J. , Lehman, Julia S. , Riemer, C A , el‐Azhary, Rokea A. , Lehman, Julia S

Mayo Clinic

British Journal of Dermatology | June 5, 2017 | Volume: 177 | Issue: 6 | Pages: 1510-1518

10.1111/bjd.15702 | PMID 28580642 Get It

Clinical commentary on ‘Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new cases’, by Wang et al.
Flanagan, Eoin P.

Mayo Clinic

Multiple Sclerosis Journal | June 5, 2017 | Volume: 23 | Issue: 14 | Pages: 1954-1955

10.1177/1352458517712867 | PMID 28580877 Get It

Using the cloud to enhance clinical teaching
Cholakian, Diana, Lippitt, Melissa, DeStephano, Christopher, DeStephano, Christopher C.

Mayo Clinic

The Clinical Teacher | June 5, 2017 | Volume: 14 | Issue: 4 | Pages: 235-241

10.1111/tct.12679 | PMID 28580694 Get It

Relationship between co‐morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia ( CLL ): a prospective cohort study
Chaffee, Kari G. , Call, Timothy G. , Achenbach, Sara J., Rabe, Kari G. , Strati, Paolo , Strati, Paolo , Parikh, Sameer A. , Kay, Neil E. , Cerhan, James R. , Slager, Susan L. , Shanafelt, Tait D.

Mayo Clinic

British Journal of Haematology | June 5, 2017 | Volume: 178 | Issue: 3 | Pages: 394-402

10.1111/bjh.14785 | PMID 28580636 Get It

Summary The ultimate cause of death for most patients with newly diagnosed chronic lymphocytic leukaemia ( CLL ) and its relationship to co‐morbid health conditions is poorly defined. We conducted a prospective cohort study that systematically followed 1143 patients diagnosed with CLL between June 2002 and November 2014. Comorbid health conditions at the time of CLL diagnosis and their relationship to survival and cause of death were evaluated. Collectively, 1061 (93%) patients had at least one co‐morbid health condition at the time of CLL diagnosis (median number 3). Despite this, 89% of patients had a low‐intermediate Charlson Comorbidity Index score ( CCI ) at diagnosis. After a median follow‐up of 6 years, 225 patients have died. Death was due to CLL progression in 85 (46%) patients, infection in 14 (8%) patients, other cancer in 35 (19%) patients and comorbid health conditions in 50 (27%) patients. Higher CCI score and a greater number of major comorbid health conditions at the time of CLL diagnosis was associated with shorter non‐ CLL specific survival, but not with shorter CLL ‐specific survival on multivariate analysis. In conclusion, CLL and CLL ‐related complications (infections and second cancers) are the overwhelming cause of death in patients with CLL , regardless of CCI score and number of comorbid health conditions at diagnosis.
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
Ruella, Marco , Klichinsky, Michael , Shestova, Olga, Ziober, Amy, Kraft, Daniel O. , Wasik, Mariusz A. , June, Carl H. , Gill, Saar , Kenderian, Saad S. , Feldman, Michael D. , Ruella, Marco

Mayo Clinic

Cancer Discovery | June 2, 2017 | Volume: 7 | Issue: 10 | Pages: 1154-1167

10.1158/2159-8290.cd-16-0850 | PMID 28576927 Get It

Abstract Patients with otherwise treatment-resistant Hodgkin lymphoma could benefit from chimeric antigen receptor T-cell (CART) therapy. However, Hodgkin lymphoma lacks CD19 and contains a highly immunosuppressive tumor microenvironment (TME). We hypothesized that in Hodgkin lymphoma, CART should target both malignant cells and the TME. We demonstrated CD123 on both Hodgkin lymphoma cells and TME, including tumor-associated macrophages (TAM). In vitro, Hodgkin lymphoma cells convert macrophages toward immunosuppressive TAMs that inhibit T-cell proliferation. In contrast, anti-CD123 CART recognized and killed TAMs, thus overcoming immunosuppression. Finally, we showed in immunodeficient mouse models that CART123 eradicated Hodgkin lymphoma and established long-term immune memory. A novel platform that targets malignant cells and the microenvironment may be needed to successfully treat malignancies with an immunosuppressive milieu. Significance: Anti-CD123 chimeric antigen receptor T cells target both the malignant cells and TAMs in Hodgkin lymphoma, thereby eliminating an important immunosuppressive component of the tumor microenvironment. Cancer Discov; 7(10); 1154–67. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 1047
Atypical Teratoid/Rhabdoid Tumor with Ependymal Differentiation : A Case Report
Utsuki, Satoshi, Kaeano, Nobuyuki, Oka, Hidehiro, Saegusa, H, Fujii, Kiyotaka, Yagishita, Saburo, W., Scheithauer Bernd, W., Scheithauer Bernd

Mayo Clinic

Japanese Journal of Neurosurgery | June 2, 2017 | Volume: 7 | Issue: 8 | Pages: 507-512

10.7887/jcns.7.507 Get It

Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease
Stonnington, Cynthia M. , Harel, Brian , Hentz, Joseph G. , Maruff, Paul , Caselli, Richard J. , Locke, Dona E.C. , Zhang, Nan , Maruff, Paul

Mayo Clinic

Alzheimer Disease & Associated Disorders | June 2, 2017 | Volume: 31 | Issue: 4 | Pages: 271-277

10.1097/wad.0000000000000200 | PMID 28582280 Get It

Introduction: This study set out to clarify the differential acute cognitive impact of lorazepam based on varying genetic risk for Alzheimer disease. Methods: Fifty-seven cognitively unimpaired individuals aged 51 to 88, genotyped according to apolipoprotein E (APOE) and translocase of outer mitochondrial membrane (40 homolog) poly-T lengths, completed cognitive testing before, 2.5 and 5 hours after receiving a 1 mg dose of lorazepam. Results: Post-lorazepam, there were significant (P<0.05) declines from baseline in memory, psychomotor processing speed, and executive function. At 2.5 hours, the magnitude of this lorazepam-induced cognitive change was significantly greater in the APOE3/4 group than in the APOE3/3 group for tests of working memory and visuospatial memory/executive function. At 5 hours postchallenge, verbal memory and working memory deficits persisted in the APOE3/4 group compared with the APOE3/3 group. At 5 hours after lorazepam challenge, as compared with the very long/very long group, the short/short group performed slightly worse on a test of working memory (P<0.05), but no other differences were observed among translocase of the outer mitochondrial membrane 40 homolog poly-T variant groups. Discussion: The lorazepam challenge may be unmasking presymptomatic cognitive dysfunction associated with APOE4 carriage.
Update on Immunohistochemical Analysis in Breast Lesions
Peng, Yan , Butt, Yasmeen M. , Chen, Beiyun, Zhang, Xinmin , Tang, Ping , Tang, Ping

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 2, 2017 | Volume: 141 | Issue: 8 | Pages: 1033-1051

10.5858/arpa.2016-0482-ra | PMID 28574279 Get It

Context.— The utility of immunohistochemistry (IHC) in breast lesions needs to be updated with exceptions among these lesions. Biomarker studies with IHC in triple-negative breast carcinoma may help develop targeted therapies for this aggressive breast cancer. The distinction of metastatic lung adenocarcinoma to the breast and invasive breast carcinoma has significant prognostic and therapeutic implications. The determination can be challenging because both primary tumors can express estrogen receptor and/or HER2 by IHC, creating a diagnostic dilemma. Objectives.— To provide a practical update on the use of IHC markers in differential diagnoses in breast lesions, including benign, atypical, precancerous, and malignant tumors; to highlight recently published research findings on novel IHC markers in triple-negative breast carcinoma cases; and to reinforce the importance of IHC use as an ancillary tool in distinguishing metastatic lung adenocarcinoma to the breast from primary breast carcinoma using real case examples. Data Sources.— PubMed (US National Library of Medicine, Bethesda, Maryland) literature review and authors' research data and personal experiences were used in this review. Conclusions.— Immunohistochemistry has an important role in making differential diagnoses in breast lesions in morphologically equivocal settings; recognizing IHC expression status in the exceptions among these lesions will aid in the correct diagnosis of challenging breast cases. Studies suggest that androgen receptor, p16, p53, GATA3, and PELP1 may have potential diagnostic, prognostic, and predictive value in triple-negative breast carcinoma cases; these findings may provide insight and a greater understanding of the tumor biology in triple-negative breast carcinomas. In distinguishing metastatic estrogen receptor–positive or HER2+ lung adenocarcinoma to the breast from primary breast carcinoma, napsin A, TTF-1, and GATA3 comprise a useful IHC panel.
Peripheral T-cell lymphomas: very little good, mainly the bad and the ugly
Ansell, Stephen M., Bennani, N. Nora

Mayo Clinic

Leukemia & Lymphoma | June 2, 2017 | Volume: 58 | Issue: 10 | Pages: 2273-2274

10.1080/10428194.2017.1326035 | PMID 28573916 Get It